Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Recruiting

Phase 3

VX-121Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Sponsor:

Vertex Pharmaceuticals Incorporated

Code:

NCT05422222

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 1 - 11

Healthy Volunteers: Not accepted

Interventions

VX-121/TEZ/D-IVA

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-31. This information was provided to ClinicalTrials.gov by Vertex Pharmaceuticals Incorporated on 2025-07-10.